Abstract: The present application describes deuterium-enriched sorafenib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched vemakalant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched donepezil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched iclaprim, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched rufinamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched olopatadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched enzastaurin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched famotidine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched olmesartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched bosentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched clazosentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched ciprofloxacin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched conivaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched raloxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched frovatriptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched clarithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched latanoprost, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched pelitrexol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.